BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock fell -2.80% on Thursday to $7.99 against a previous-day closing price of $8.22. With 2.35 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.9 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $8.21 whereas the lowest price it dropped to was $7.91. The 52-week range on BCRX shows that it touched its highest point at $15.43 and its lowest point at $7.20 during that stretch. It currently has a 1-year price target of $15.15. Beta for the stock currently stands at 1.97.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BCRX was down-trending over the past week, with a drop of -4.54%, but this was up by 4.86% over a month. Three-month performance dropped to -12.20% while six-month performance fell -37.09%. The stock lost -6.77% in the past year, while it has lost -30.40% so far this year. A look at the trailing 12-month EPS for BCRX yields -1.21 with Next year EPS estimates of -0.54. For the next quarter, that number is -0.23. This implies an EPS growth rate of -29.40% for this year and 43.20% for next year. EPS is expected to grow by 44.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -11.30%.
Float and Shares Shorts:
At present, 188.51 million BCRX shares are outstanding with a float of 184.56 million shares on hand for trading. On Apr 27, 2023, short shares totaled 31.2 million, which was 16.52% higher than short shares on Mar 30, 2023. In addition to Mr. Jon P. Stonehouse as the firm’s CEO, Pres & Exec. Director, Mr. Anthony J. Doyle serves as its Sr. VP & CFO.
Through their ownership of 87.07% of BCRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 54.99% of BCRX, in contrast to 34.74% held by mutual funds. Shares owned by individuals account for 12.54%. As the largest shareholder in BCRX with 7.63% of the stake, The Vanguard Group, Inc. holds 14,373,362 shares worth 14,373,362. A second-largest stockholder of BCRX, BlackRock Fund Advisors, holds 12,909,618 shares, controlling over 6.85% of the firm’s shares. Baker Bros. Advisors LP is the third largest shareholder in BCRX, holding 12,710,818 shares or 6.75% stake. With a 3.75% stake in BCRX, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 7,068,485 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 3.06% of BCRX stock, is the second-largest Mutual Fund holder. It holds 5,761,193 shares valued at 43.84 million. iShares Russell 2000 ETF holds 2.09% of the stake in BCRX, owning 3,937,310 shares worth 29.96 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, BCRX reported revenue of $65.53M and operating income of -$34.72M. The EBITDA in the recently reported quarter was -$34.11M and diluted EPS was -$0.32.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BCRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BCRX analysts setting a high price target of $30.00 and a low target of $8.00, the average target price over the next 12 months is $14.95. Based on these targets, BCRX could surge 275.47% to reach the target high and rise by 0.13% to reach the target low. Reaching the average price target will result in a growth of 87.11% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded BCRX stock several times over the past three months with 5 Buys and 1 Sells. In these transactions, 35,855 shares were bought while 7,000 shares were sold. The number of buy transactions has increased to 43 while that of sell transactions has risen to 13 over the past year. The total number of shares bought during that period was 1,036,113 while 488,333 shares were sold.